XML 136 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Disclosures - Summary of Significant Expenses (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Non-cash stock compensation $ 8,527,000 $ 7,102,000
Total operating expenses 98,052,000 99,223,000
Loss from operations (98,052,000) (99,223,000)
Interest income 3,390,000 3,075,000
Change in fair value of the tranche rights (4,796,000) 0
Other income (expense) (1,049,000) 2,536,000
Net loss (100,507,000) (93,612,000)
Reportable Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Clinical product candidates 65,285,000 68,999,000
Pre-clinical product candidates 979,000 1,995,000
Employee costs-general and administrative 5,315,000 4,478,000
Non-cash stock compensation 8,527,000 7,102,000
Professional fees and other segment expenses 9,958,000 9,621,000
Total operating expenses 98,052,000 99,223,000
Loss from operations (98,052,000) (99,223,000)
Interest income 3,390,000 3,075,000
Change in fair value of the tranche rights (4,796,000) 0
Other income (expense) (1,049,000) 2,536,000
Net loss $ (100,507,000) $ (93,612,000)